Eesti - eesti - Ravimiamet

teva b.v. - paklitakseel - infusioonilahuse kontsentraat - 6mg 1ml 50ml 1tk; 6mg 1ml 25ml 1tk; 6mg 1ml 5ml 1tk; 6mg 1ml 16.7ml 1tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - paklitakseel - infusioonilahuse kontsentraat - 6mg 1ml 5ml 20tk; 6mg 1ml 16.7ml 20tk; 6mg 1ml 50ml 1tk; 6mg 1ml 5ml 10tk; 6mg 1ml 100ml 20tk; 6mg 1ml 25ml 5tk; 6mg 1ml 25ml 20tk; 6mg 1ml 16.7ml 10tk; 6mg 1ml 5ml 1tk; 6mg 1ml 25ml 1tk; 6mg 1ml 100ml 10tk; 6mg 1ml 25ml 10tk; 6mg 1ml 100ml 1tk; 6mg 1ml 50ml 5tk; 6mg 1ml 5ml 5tk; 6mg 1ml 100ml 5tk; 6mg 1ml 50ml 10tk; 6mg 1ml 50ml 20tk

Eesti - eesti - Ravimiamet

uab sanoswiss - paklitakseel - infusioonilahuse kontsentraat - 6mg 1ml 5ml 1tk; 6mg 1ml 50ml 1tk; 6mg 1ml 25ml 1tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - paklitakseel - infusioonilahuse kontsentraat - 6mg 1ml 50ml 1tk; 6mg 1ml 5ml 1tk; 6mg 1ml 25ml 1tk; 6mg 1ml 16.7ml 1tk

Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - paklitakseel - infusioonilahuse kontsentraat - 6mg 1ml 16.7ml 1tk; 6mg 1ml 5ml 5tk; 6mg 1ml 100ml 5tk; 6mg 1ml 50ml 1tk; 6mg 1ml 50ml 5tk; 6mg 1ml 100ml 1tk; 6mg 1ml 5ml 1tk; 6mg 1ml 25ml 1tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - paklitakseel - infusioonilahuse kontsentraat - 6mg 1ml 25ml 1tk; 6mg 1ml 5ml 1tk; 6mg 1ml 16.7ml 1tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - paklitakseel - infusioonilahuse kontsentraat - 6mg 1ml 16.7ml 1tk; 6mg 1ml 25ml 1tk; 6mg 1ml 50ml 1tk; 6mg 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

hospira uk limited - paklitakseel - infusioonilahuse kontsentraat - 6mg 1ml 25ml 1tk; 6mg 1ml 50ml 1tk; 6mg 1ml 5ml 1tk

Eesti - eesti - Ecolab

ecolab deutschland gmbh -

Euroopa Liit - eesti - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.